A. Z.Bluming

C. A.Singer

D.Applebaum-Bowden

E.Barrett-Connor

E.Hogervorst

E.Hoibraaten

G.Gregoriou

H. K.Cho

H.Jokela

J. C.Stevenson

J. M.Martinez-Lage

P. M.Doraiswamy

P.Lopes

R. D.Brinton

S. R.Rapp

T.Sporrong

W. A.Rocca

Many trials on the use of hormone replacement therapy (HRT) have provided contradictory results on its risks and benefits in post-menopausal women. The use of HRT declined globally following publication of the first data from the Women’s Health Initiative (WHI) trial in 2002, with the revelation that there was an increased risk of breast cancer and coronary heart disease (CHD) in postmenopausal women taking HRT. Following this, other leading studies published results that were consistent with these findings, which reduced enthusiasm for HRT use. However, recent publications from the International Menopause Society indicate that HRT is the first-line and most effective treatment for menopausal symptoms. Moreover, when the full results of the WHI trial were subsequently published, it appeared that HRT may confer benefits for CHD prevention below age 60. The statements from the British Menopause Society and the International Menopause Society (IMS) published in 2008 also supported this opinion. These revelations renew interest in HRT use. This paper analyzes the effects of combination versus unopposed HRT on osteoporosis, breast and CHD, endometrial cancer induction, venous thromboembolic disease, lipids and lipoproteins, neuroprotection, and cognitive function in post-menopausal women.</p

Geer Mohammad Ishaq

Pz Tasaduq Hussain

Mir Javid Iqbal

Mohsin Bin Mushtaq

Crossref

International Journal of User-Driven Healthcare

Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women

Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women

Abstract

Similar works

Full text

Available Versions

Crossref